Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) COO B Lynne Parshall sold 16,118 shares of the company’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total value of $1,047,670.00. Following the sale, the chief operating officer now owns 33,526 shares of the company’s stock, valued at $2,179,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded up 1.15% on Friday, reaching $64.39. The company had a trading volume of 1,631,810 shares. The company has a 50-day moving average price of $56.15 and a 200-day moving average price of $50.31. The firm has a market capitalization of $8.01 billion, a PE ratio of 309.57 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.58 and a 52-week high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company’s revenue for the quarter was up 170.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. Equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.16) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/20/b-lynne-parshall-sells-16118-shares-of-ionis-pharmaceuticals-inc-ions-stock.html.

IONS has been the subject of several research analyst reports. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research note on Monday, July 31st. Jefferies Group LLC reaffirmed an “underperform” rating and issued a $18.00 target price (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. Sanford C. Bernstein began coverage on Ionis Pharmaceuticals in a research report on Thursday, July 27th. They issued a “market perform” rating and a $57.00 target price for the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 target price (up previously from $59.00) on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 12th. Finally, Barclays PLC decreased their target price on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a research report on Thursday, September 21st. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $50.04.

Institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC increased its stake in shares of Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after purchasing an additional 800 shares during the period. Aviva PLC bought a new position in shares of Ionis Pharmaceuticals in the second quarter worth about $10,187,000. Credit Suisse AG increased its stake in shares of Ionis Pharmaceuticals by 79.2% in the first quarter. Credit Suisse AG now owns 385,145 shares of the company’s stock worth $15,483,000 after purchasing an additional 170,192 shares during the period. Allen Investment Management LLC increased its stake in shares of Ionis Pharmaceuticals by 64.7% in the second quarter. Allen Investment Management LLC now owns 15,652 shares of the company’s stock worth $796,000 after purchasing an additional 6,147 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Ionis Pharmaceuticals by 21.4% in the second quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after purchasing an additional 3,538 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.